(Q42877580)

9 November 2017

Phosphoramidate prodrugs deliver with potency against hepatitis C virus (English)

1 reference

9 November 2017

Youcef Mehellou

1

0 references

publication date

1 November 2010

1 reference

9 November 2017

1 reference

9 November 2017

5

1 reference

9 November 2017

11

1 reference

9 November 2017

1841-1842

1 reference

Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

9 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Nucleoside analogues and nucleobases in cancer treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Emerging drugs for hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Prodrugs of phosphates and phosphonates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000310

7 January 2021

Identifiers

DOI

10.1002/CMDC.201000310

1 reference

9 November 2017

1 reference

PubMed ID

20865770